CAZITEL PLUS XL TABLETS FOR DOGS

País: Irlanda

Idioma: inglés

Fuente: HPRA (Health Products Regulatory Authority)

Cómpralo ahora

Ficha técnica Ficha técnica (SPC)
15-04-2017

Ingredientes activos:

PRAZIQUANTEL, PYRANTEL EMBONATE PH.EUR (EQUIVALENT TO 175 MG PYRANTEL), FEBANTEL

Disponible desde:

Chanelle Pharmaceuticals Manufacturing Limited

Código ATC:

QP52AA01

Designación común internacional (DCI):

PRAZIQUANTEL, PYRANTEL EMBONATE PH.EUR (EQUIVALENT TO 175 MG PYRANTEL), FEBANTEL

Dosis:

175/504/52 mg/tablet

formulario farmacéutico:

Tablets

tipo de receta:

CAM-Companion Animal Medicine

Grupo terapéutico:

Canine

Área terapéutica:

Praziquantel QP52AC05 Febantel QP52AF02 Pyrantel

indicaciones terapéuticas:

Endoparasiticide

Estado de Autorización:

Authorised

Fecha de autorización:

2012-03-02

Ficha técnica

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Cazitel Plus XL Tablets For Dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCES:
Praziquantel
175 mg
Pyrantel Embonate
504 mg (equivalent to 175 mg pyrantel)
Febantel
525 mg
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet
A yellow coloured oblong tablet with a breakline on both sides.
The tablets can be divided into two equal parts.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In adult dogs: Treatment of mixed infections by nematodes and cestodes
of the following species
NEMATODES:
ASCARIDS:_ Toxocara canis_,_ Toxascaris leonina_ (adult and late
immature forms).
HOOKWORMS:_ Uncinaria stenocephala_,_ Ancylostoma caninum_ (adults).
WHIPWORMS:_ Trichuris vulpis_ (adults).
CESTODES:
TAPEWORMS:_ Echinococcus_ species,_ (E. granulosus, E.
multilocularis), Taenia_ species,
_(T. hydatigena, T. pisiformis, T. taeniformis), Dipylidium caninum_
(adult and immature forms).
4.3 CONTRAINDICATIONS
Do not use simultaneously with piperazine compounds.
Do not use in animals with a known sensitivity to the active
ingredients or to any of the excipients.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_3_
_1_
_/_
_0_
_3_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_4_
_6_
_6_
_9_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Fleas s
                                
                                Leer el documento completo